epirubicin has been researched along with T-Cell Lymphoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Chu, X; Liu, X; Wang, Y; Xu, L | 1 |
| Baines, S; Elliott, J | 1 |
| Choi, CW; Choi, IK; Choi, JG; Kim, BS; Kim, JS; Kim, SJ; Kim, YH; Oh, SC; Park, KH; Seo, HY; Seo, JH; Shin, SW; Sul, HR; Sung, HJ | 1 |
| Choi, CW; Jung, KY; Kim, BS; Kim, CY; Kim, IS; Kim, JS; Kim, SJ; Seo, HY; Seol, HR; Sung, HJ | 1 |
| Bu, Q; Cai, QQ; Gao, Y; Guan, ZZ; Huang, HQ; Jiang, WQ; Lin, XB; Pan, ZH; Wang, BF; Xia, ZJ; Xu, RH | 1 |
5 other study(ies) available for epirubicin and T-Cell Lymphoma
| Article | Year |
|---|---|
Successful treatment of hemophagocytic syndrome in a patient with T cell lymphoma, EBV infection, and bone marrow necrosis: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Epstein-Barr Virus Infections; Etoposide; Glucocorticoids; Herpesvirus 4, Human; Humans; Lymphohistiocytosis, Hemophagocytic; Lymphoma, T-Cell; Male; Middle Aged; Positron-Emission Tomography; Rituximab; Treatment Outcome; Vincristine | 2022 |
A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017).
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dog Diseases; Dogs; Epirubicin; Female; Lomustine; Lymphoma, T-Cell; Male; Neutropenia; Prednisolone; Retrospective Studies; United Kingdom; Vincristine | 2019 |
Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Cells; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Neutropenia; Prednisone; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome; Vincristine | 2006 |
Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Killer Cells, Natural; Lymphoma, T-Cell; Male; Middle Aged; Prednisone; Proportional Hazards Models; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Vincristine | 2006 |
[CEOP regimen in the treatment for non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Middle Aged; Neoplasm Staging; Neutropenia; Prednisone; Remission Induction; Retrospective Studies; Survival Analysis; Thrombocytopenia; Vincristine | 2007 |